Empagliflozin
Empagliflozin may reduce ventricular arrhythmias in patients with type 2 diabetes, ICDs
PHILADELPHIA — In the EMPA-ICD trial, patients with type 2 diabetes and an implantable cardioverter defibrillator had fewer ventricular arrhythmias at 24 weeks when assigned empagliflozin compared with placebo.
Women at significant risk for urinary, genital infections while using SGLT2i
SAN DIEGO — Women with autoimmune and rheumatic conditions are at a significant risk for adverse events during treatment with sodium glucose cotransporter 2 inhibitors, according to data presented at ACR Convergence 2023.
Top in endocrinology: FDA OKs empagliflozin for kids; hormonal effects of brain injury
The FDA has approved new oral therapies for children with type 2 diabetes — empagliflozin and a combination of empagliflozin and metformin hydrochloride — for the first time in more than 20 years.
FDA approves empagliflozin for use among children with type 2 diabetes
The FDA has approved two forms of empagliflozin as an adjunct to diet and exercise to improve glycemic control in children with type 2 diabetes, according to a press release.
Quadruple therapy borderline cost-effective for HFrEF; drug prices continue to rise
Researchers reported quadruple therapy with SGLT2 and angiotensin receptor-neprilysin inhibition was narrowly cost-effective compared with standard care plus SGLT2 inhibition alone for patients with HF and reduced ejection fraction.
Empagliflozin HF benefits extend across spectrum of kidney disease
Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.
Empagliflozin may lower AF risk by improving certain parameters of left atrial function
The antiarrhythmic benefits of empagliflozin in patients with and without diabetes may be explained by the SGLT2 inhibitor’s ability to improve left atrial strain reservoir and contraction phase values, researchers reported.
Advocacy plays an important role in advancing kidney-related legislation
SCOTTSDALE, Ariz. — Advocacy groups succeeded at placing kidney disease front-and-center on the roadmap to legislative support in Washington, but more improvements are needed, according to presenters at the Southwest Nephrology Conference.
Empagliflozin benefits consistent regardless of timing of HF hospitalization
NEW ORLEANS — The benefits of empagliflozin in patients with HF were consistent regardless of the recency of a patient’s HF hospitalization, researchers reported at the American College of Cardiology Scientific Session.
Top in endocrinology: Social stigma in diabetes; empagliflozin adjunctive therapy
Most adults with type 1 or type 2 diabetes in the United States reported experiencing social stigma, and many also reported that social stigma impacted their decision to not use an insulin pump or continuous glucose monitoring device, data show.